MA46965B1 - Modulateurs de gamma ror (rory) - Google Patents

Modulateurs de gamma ror (rory)

Info

Publication number
MA46965B1
MA46965B1 MA46965A MA46965A MA46965B1 MA 46965 B1 MA46965 B1 MA 46965B1 MA 46965 A MA46965 A MA 46965A MA 46965 A MA46965 A MA 46965A MA 46965 B1 MA46965 B1 MA 46965B1
Authority
MA
Morocco
Prior art keywords
rory
ror
modulators
gamma
formula
Prior art date
Application number
MA46965A
Other languages
English (en)
Inventor
Joseph Maria Gerardus Barbara Cals
David Machnik
Sander Bernardus Nabuurs
Jean-François Sabuco
Original Assignee
Sanofi Sa
Lead Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Lead Pharma B V filed Critical Sanofi Sa
Publication of MA46965B1 publication Critical patent/MA46965B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

La présente invention concerne des composés selon (formule ia) ou (formule ib) : (formule ia) (formule ib) ou un sel pharmaceutiquement acceptable de ceux-ci. Les composés peuvent être utilisés en tant qu'inhibiteurs du rory et sont utiles pour le traitement de maladies à médiation assurée par rory.
MA46965A 2016-12-05 2017-12-05 Modulateurs de gamma ror (rory) MA46965B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16202175 2016-12-05
PCT/EP2017/081489 WO2018104288A1 (fr) 2016-12-05 2017-12-05 MODULATEURS DE ROR GAMMA (RORγ)

Publications (1)

Publication Number Publication Date
MA46965B1 true MA46965B1 (fr) 2020-12-31

Family

ID=57482312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46965A MA46965B1 (fr) 2016-12-05 2017-12-05 Modulateurs de gamma ror (rory)

Country Status (33)

Country Link
US (3) US10196350B2 (fr)
EP (1) EP3548016B1 (fr)
JP (1) JP6955563B2 (fr)
KR (1) KR102554776B1 (fr)
CN (1) CN110352054B (fr)
AR (1) AR110481A1 (fr)
AU (1) AU2017373593B2 (fr)
CA (1) CA3045946A1 (fr)
CL (1) CL2019001406A1 (fr)
CO (1) CO2019007186A2 (fr)
CR (1) CR20190321A (fr)
DK (1) DK3548016T3 (fr)
DO (1) DOP2019000119A (fr)
EA (1) EA201991373A1 (fr)
EC (1) ECSP19047767A (fr)
ES (1) ES2830759T3 (fr)
HU (1) HUE052470T2 (fr)
IL (1) IL267045B (fr)
LT (1) LT3548016T (fr)
MA (1) MA46965B1 (fr)
MX (1) MX389171B (fr)
MY (1) MY194174A (fr)
NZ (1) NZ755105A (fr)
PE (1) PE20191545A1 (fr)
PH (1) PH12019501231A1 (fr)
PL (1) PL3548016T3 (fr)
PT (1) PT3548016T (fr)
RS (1) RS60964B1 (fr)
TW (1) TWI705958B (fr)
UA (1) UA123751C2 (fr)
UY (1) UY37507A (fr)
WO (1) WO2018104288A1 (fr)
ZA (1) ZA201902288B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101009A1 (fr) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Modulateurs de gamma ror (rory)
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
WO2023232870A1 (fr) 2022-05-31 2023-12-07 Immunic Ag Modulateurs de rorg/rorgt pour le traitement d'infections virales de type covid-19

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2572334A1 (fr) 2004-07-01 2006-01-19 New York University Compositions et procedes pour la modulation du ror.gamma.t
WO2011115892A1 (fr) 2010-03-15 2011-09-22 Griffin Patrick R Modulateurs des récepteurs orphelins liés au récepteur de l'acide rétinoïque
WO2013029338A1 (fr) 2011-09-01 2013-03-07 Glaxo Group Limited Nouveaux composés
WO2013169864A2 (fr) 2012-05-08 2013-11-14 Lycera Corporation Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie
WO2013171729A2 (fr) * 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Composés d'aryl- et hétéroarylamide en tant que modulateur de rorγt
US9359315B2 (en) 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
UA117941C2 (uk) 2013-12-05 2018-10-25 Лід Фарма Холдінг Б.В. МОДУЛЯТОРИ ROR-ГAMMA (RORγ)
TW201605797A (zh) 2013-12-10 2016-02-16 葛蘭馬克製藥公司 作為ror伽馬調節物的雙環雜芳基化合物
WO2015090507A1 (fr) 2013-12-19 2015-06-25 Merck Patent Gmbh Tétrahydrotétrazolo[1,5-a]pyrazines utilisées comme inhibiteurs du ror-gamma
WO2015101928A1 (fr) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Dérivés de thiophène et de thiazole fusionnés utilisés en tant que modulateurs gamma ror
RS59007B1 (sr) 2014-02-03 2019-08-30 Vitae Pharmaceuticals Llc Dihidropirolopiridinski inhibitori ror-gama
EP3122721A4 (fr) * 2014-03-27 2018-01-10 Piramal Enterprises Limited Modulateurs de ror-gamma et leurs utilisations
WO2015160654A1 (fr) 2014-04-14 2015-10-22 Boehringer Ingelheim International Gmbh Composés utilisés comme modulateurs de ror gamma
MX394388B (es) 2015-05-15 2025-03-21 Aurigene Discovery Tech Ltd Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma
EP3101009A1 (fr) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Modulateurs de gamma ror (rory)
EP3101006A1 (fr) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Modulateurs de gamma ror (rory)
EP3101007A1 (fr) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Modulateurs de gamma ror (rory)
EP3101005A1 (fr) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Modulateurs de gamma ror (rory)
EP3101008A1 (fr) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Modulateurs de gamma ror (rory)
MY198809A (en) 2015-08-03 2023-09-28 Glenmark Pharmaceuticals Sa Novel compounds as ror gamma modulators
WO2017213137A1 (fr) 2016-06-09 2017-12-14 アグロカネショウ株式会社 Nouveau composé et produit chimique agricole/horticole l'utilisant comme ingrédient actif
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
JP2019026575A (ja) 2017-07-27 2019-02-21 アグロカネショウ株式会社 新規化合物およびこれを有効成分とする農園芸用殺菌剤

Also Published As

Publication number Publication date
US20180162808A1 (en) 2018-06-14
WO2018104288A1 (fr) 2018-06-14
EA201991373A1 (ru) 2019-11-29
US11299456B2 (en) 2022-04-12
US20190119204A1 (en) 2019-04-25
PH12019501231A1 (en) 2019-09-23
CO2019007186A2 (es) 2019-08-20
CR20190321A (es) 2019-09-11
ES2830759T3 (es) 2021-06-04
JP6955563B2 (ja) 2021-10-27
TW201835038A (zh) 2018-10-01
NZ755105A (en) 2023-01-27
CN110352054A (zh) 2019-10-18
DOP2019000119A (es) 2019-09-30
ZA201902288B (en) 2020-10-28
LT3548016T (lt) 2021-01-11
PE20191545A1 (es) 2019-10-24
MX2019006517A (es) 2019-08-22
AR110481A1 (es) 2019-04-03
DK3548016T3 (da) 2020-11-16
HUE052470T2 (hu) 2022-02-28
ECSP19047767A (es) 2019-08-30
RS60964B1 (sr) 2020-11-30
US20200190028A1 (en) 2020-06-18
AU2017373593A1 (en) 2019-07-25
EP3548016A1 (fr) 2019-10-09
CA3045946A1 (fr) 2018-06-14
UA123751C2 (uk) 2021-05-26
MY194174A (en) 2022-11-17
CL2019001406A1 (es) 2019-10-18
MX389171B (es) 2025-03-20
TWI705958B (zh) 2020-10-01
KR102554776B1 (ko) 2023-07-11
IL267045B (en) 2021-07-29
JP2020500886A (ja) 2020-01-16
NZ794287A (en) 2025-02-28
PT3548016T (pt) 2020-10-08
IL267045A (en) 2019-07-31
CN110352054B (zh) 2022-11-01
KR20190096365A (ko) 2019-08-19
UY37507A (es) 2018-06-29
EP3548016B1 (fr) 2020-09-02
US10196350B2 (en) 2019-02-05
AU2017373593B2 (en) 2022-04-07
BR112019010461A2 (pt) 2019-09-10
PL3548016T3 (pl) 2021-02-08

Similar Documents

Publication Publication Date Title
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA43828B1 (fr) Agents thérapeutiques pour maladies neurodégénératives
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA40769B1 (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA39427A1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA49055B1 (fr) Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf
MY208400A (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MA40886B1 (fr) Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
MA46965B1 (fr) Modulateurs de gamma ror (rory)
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines